Neurogene
NGNE
39 hedge funds and large institutions have $384M invested in Neurogene in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 8 closing their positions.
0.08% less ownership
Funds ownership: 5% → 4.92% (-0.08%)
1% less capital invested
Capital invested by funds: $386M → $384M (-$2.13M)
18% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 17
20% less funds holding
Funds holding: 49 → 39 (-10)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
57% less call options, than puts
Call options by funds: $412K | Put options by funds: $950K
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$26.5M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$6.99M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$452K |
| 4 |
AP
Archon Partners
Princeton Junction,
New Jersey
|
+$220K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$209K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.95M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.51M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.25M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$1.26M |
| 5 |
Morgan Stanley
New York
|
-$847K |
NGNE Hedge Fund Activity: Q1 2017 in Review
39 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q1 2017, worth a combined $384M — down 0.55% from $386M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of NGNE and 3 opened new positions — a net loss of 5 holders — while 17 trimmed existing stakes and 14 added.
The largest buyer was BlackRock, adding an estimated $26.5M. The largest seller was Opaleye Management, cutting an estimated $3.95M.
- 39 institutional investors held Neurogene (NGNE) as of Q1 2017, down from 49 in Q4 2016.
- Funds reported $384M of Neurogene stock for Q1 2017, down 0.55% quarter-over-quarter.
- 3 funds opened new Neurogene positions in Q1 2017 and 8 closed out, a net change of -5 holders.
- The largest Neurogene buyer in Q1 2017 was BlackRock, an estimated $26.5M added.
- The largest Neurogene seller in Q1 2017 was Opaleye Management, an estimated $3.95M sold.
Based on aggregated 13F filings for Q1 2017.